Kimberly Lynn Blackwell, MD

Adjunct Professor in the Department of Medicine
Member of the Duke Cancer Institute
Campus mail Duke Box 3893, Durham, NC 27710
Phone (919) 668-1748
Email address black034@mc.duke.edu

Breast cancer angiogenesis
Breast cancer in younger women
Hormonal therapy
Neoadjurant therapy for breast cancer

Current Clinical Investigations

Principal Investigator, A Phase I-II Study of Neoadjuvant Evacet/Paclitaxel/Hyperthermia in Locally Advanced Breast Cancer Patients.

Investigator, Development of Screening Markers for Breast Cancer using Circulating Immune Complexes: Collaborative Study with Diagen Medical Technologies.

Principal Investigator, Use of Plasma D-Dimer as a Predictive Marker in Colorectal Carcinoma: Correlative Science Study with Genentech, Inc.

Principal Investigator, A randomized, Phase II study of gabapentin or glutamine to prevent the peripheral neuropathy/myalgia associated with weekly taxol administration in metastatic breast and lung cancer.

Investigator, A Phase 2, Randomized, Double-Masked, Multicenter Study of Two Dose Levels of ERA-923 for the treatment of Metastatic Breast Cancer in Postmenopausal Women who have failed Tamoxifen therapy. Genetics Institute.

Investigator, A Phase I Study of Combined Doxil/Hyperthermia in Stage IV Breast Cancer.

Education and Training

  • Fellow in Hematology-Oncology, Medicine, Duke University, 1997 - 2000
  • Medical Resident, Medicine, Duke University, 1994 - 1997
  • M.D., Mayo School of Health Sciences, 1994

Publications

Hardee, M. E., J. P. Kirkpatrick, S. Shan, S. A. Snyder, Z. Vujaskovic, Z. N. Rabbani, M. W. Dewhirst, and K. L. Blackwell. “Human recombinant erythropoietin (rEpo) has no effect on tumour growth or angiogenesis..” Br J Cancer 93, no. 12 (December 12, 2005): 1350–55. https://doi.org/10.1038/sj.bjc.6602846.

PMID
16288305
Full Text

Craciunescu, O. I., E. L. Jones, K. L. Blackwell, T. Z. Wong, E. L. Rosen, Z. Vujaskovic, J. R. MacFall, et al. “Characterizing tumor changes during neoadjuvant treatment of locally advanced breast cancer patients (LABC) using dynamicenhanced magnetic resonance imaging (DE-MRI).” Progress in Biomedical Optics and Imaging  Proceedings of Spie 5698 (August 16, 2005): 116–25. https://doi.org/10.1117/12.591173.

Full Text

Burris, Howard A., Herbert I. Hurwitz, E Claire Dees, Afshin Dowlati, Kimberly L. Blackwell, Bert O’Neil, Paul K. Marcom, et al. “Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas..” J Clin Oncol 23, no. 23 (August 10, 2005): 5305–13. https://doi.org/10.1200/JCO.2005.16.584.

PMID
15955900
Full Text

Spector, Neil L., Wenle Xia, Howard Burris, Herbert Hurwitz, E Claire Dees, Afshin Dowlati, Bert O’Neil, et al. “Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies..” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 23, no. 11 (April 2005): 2502–12. https://doi.org/10.1200/jco.2005.12.157.

PMID
15684311
Full Text

Craciunescu, O., K. Blackwell, T. Wong, E. Rosen, T. Raidy, E. Jones, Z. Vujaskovic, et al. “SU‐EE‐A2‐06: Non‐Contact, Non‐Invasive Breast Thermography Has Potential to Evaluate Treatment Response in Breast Cancer Patients.” In Medical Physics, Vol. 32, 2005. https://doi.org/10.1118/1.1997458.

Full Text

Chu, Isabel, Kimberly Blackwell, Susie Chen, and Joyce Slingerland. “The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer..” Cancer Research 65, no. 1 (January 2005): 18–25. https://doi.org/10.1158/0008-5472.can-04-3270.

PMID
15665275
Full Text

Daniel, B. R., and K. Blackwell. “Ectopic breast cancer: Rare, treatable, and potentially curable.” Community Oncology 2, no. 2 (January 1, 2005): 120–22. https://doi.org/10.1016/S1548-5315(11)70864-6.

Full Text

Rosen, E. L., K. L. Blackwell, J. A. Baker, and S. G. Orel. “Accuracy of MRI in the detection of residual breast cancer after neoadjuvant chemotherapy.” Breast Diseases 15, no. 2 (July 1, 2004): 140–42.

Scholars@Duke

Alvarez Secord, Angeles, Robyn Sayer, Stacey A. Snyder, Gloria Broadwater, Gustavo C. Rodriguez, Andrew Berchuck, and Kimberly Blackwell. “The relationship between serum vascular endothelial growth factor, persistent disease, and survival at second-look laparotomy in ovarian cancer..” Gynecologic Oncology 94, no. 1 (July 2004): 74–79. https://doi.org/10.1016/j.ygyno.2004.03.043.

PMID
15262122
Full Text

Blackwell, Kimberly, Herbert Hurwitz, Grazyna Liebérman, William Novotny, Stacey Snyder, Mark Dewhirst, and Charles Greenberg. “Circulating D-dimer levels are better predictors of overall survival and disease progression than carcinoembryonic antigen levels in patients with metastatic colorectal carcinoma..” Cancer 101, no. 1 (July 2004): 77–82. https://doi.org/10.1002/cncr.20336.

PMID
15221991
Full Text

Pages